21 - 40 of about 59
English: Okazaki S, Sasaki T, Yasuda S, Abe M, Yoshida N, Yoshida R, Ishibashi K, Minami Y, Okumura S, Chiba S, Takei H, Hayashi R, Nagato T, Kobayashi H, Sugitani A, Ono Y, Mizukami Y, Kitada M, Ohsaki Y., The feasibility of circulating tumor DNA analysis as a marker of recurrence in triple-negative breast cancer , Oncol Letter , vol.21 (5) (p.420 - ) , 2021
English: Fukudo M, Ishibashi K, Kitada M., Real-world pharmacokinetics and pharmacodynamics of everolimus in metastatic breast cancer. , New Drugs , 2021
English: Yamashita T, Kawaguchi H, Masuda N, Kitada M, Narui K, Hattori M, Yoshinami T, Matsunami N, Yanagihara K, Kawasoe T, Nagashima T, Bando H, Yano H, Hasegawa Y, Nakamura R, Kashiwaba M, Morita S, Ohno S, Toi M., Efficacy of the eribulin, pertuzumab, and trastuzumab combination therapy for human epidermal growth factor receptor 2-positive advanced or metastatic breast cancer: a multicenter, single arm, phase II study (JBCRG-M03 study). , Invest New Drugs. , vol.39 (1) (p.217 - 225) , 2021
English: Toi M, Imoto S, Ishida T, Ito Y, Iwata H, Masuda N, Mukai H, Saji S, Shimizu A, Ikeda T, Haga H, Saeki T, Aogi K, Sugie T, Ueno T, Kinoshita T, Kai Y, Kitada M, Sato Y, Jimbo K, Sato N, Ishiguro H, Takada M, Ohashi Y, Ohno S., Adjuvant S-1 plus endocrine therapy for oestrogen receptor-positive, HER2-negative, primary breast cancer: a multicentre, open-label, randomised, controlled, phase 3 trial. , Lancet Oncology , vol.22 (1) (p.74 - 84) , 2021
English: Yamashita T, Masuda N, Saji S, Araki K, Ito Y, Takano T, Takahashi M, Tsurutani J, Koizumi K, Kitada M, Kojima Y, Sagara Y, Tada H, Iwasa T, Kadoya T, Iwatani T, Hasegawa H, Morita S, Ohno S., Correction to: Trastuzumab, pertuzumab, and eribulin mesylate versus trastuzumab, pertuzumab, and a taxane as a first-line or second-line treatment for HER2-positive, locally advanced or metastatic breast cancer: study protocol for a randomized controlled, non-inferiority, phase III trial in Japan (JBCRG-M06/EMERALD). , Trials , vol.21 (1) (p.503 - ) , 2020
English: Yamashita T, Masuda N, Saji S, Araki K, Ito Y, Takano T, Takahashi M, Tsurutani J, Koizumi K, Kitada M, Kojima Y, Sagara Y, Tada H, Iwasa T, Kadoya T, Iwatani T, Hasegawa H, Morita S, Ohno S, Trastuzumab, pertuzumab, and eribulin mesylate versus trastuzumab, pertuzumab, and a taxane as a first-line or second-line treatment for HER2-positive, locally advanced or metastatic breast cancer: study protocol for a randomized controlled, non-inferiority, phase III trial in Japan (JBCRG-M06/EMERALD). , Trials , vol.21 (1) (p.391 - ) , 2020 , (IF:2.05)
English: Hirai N, Sasaki T, Okumura S, Sado M, Akiyama N, Kitada M, Takei H, Ohsaki Y, Novel ALK-specific mRNA in situ hybridization assay for non-small-cell lung carcinoma. , Transl Lung Cancer Res. , vol.9 (2) (p.257 - 268) , 2020
English: Masahiro Kitada, MD, Shunsuke Yasuda, Masahiro Abe, Nana Yoshida, Satoshi Okazaki and Kei Ishibashi. , HER2 Type Male Breast Cancer Successfully Treated with Pertuzumab, Trastuzumab, and Eribulin Therapy: A Case Report , Journal of Cancer Therapy , vol.11 (p.154 - 159) , 2020
English: Uno Y, Akiyama N, Yuzawa S, Kitada M, Takei H., The value and practical utility of intraoperative touch imprint cytology of sentinel lymph node(s) in patients with breast cancer: A retrospective cytology-histology correlation study. , Cytojournal , vol.17 (11) , 2020
English: Kitada M, Yasuda S, Abe M, et al. , Difficult-to-Diagnose Hormone-Negative, Human Epidermal Growth Factor Receptor 2-Positive Poorly-Differentiated Breast Cancer in a Male Patient. , Ann Breast Cancer Therapy , vol.4 (1) (p.44 - 47) , 2020
English: Kitada M, Yasuda S, Abe M, Yoshida N, Okazaki S, Ishibashi K, Solitary fibrous tumor of the trachea: a case report. , Gen Thorac Cardiovasc Surg. , vol.68 (12) (p.1523 - 1527) , 2019
English: Masahiro Kitada, MD, Shunsuke Yasuda, Masahiro Abe, Nana Yoshida, Satoshi Okazaki and Kei Ishibashi., Hormone-Negative,Her2-Positive Male Breast Cancer with a Poor Prognosis: A Case Report. , Annals of Breast Cancer and Therapy , 2019
English: Yoshida R, Sasaki T, Minami Y, Hibino Y, Okumura S, Sado M, Miyokawa N, Hayashi S, Kitada M, Ohsaki Y., Activation of Src signaling mediates acquired resistance to ALK inhibition in lung cancer. , Int J Oncol. , vol.51 (5) (p.1533 - 1540) , 2017
English: Kitada M, Yasuda S, Takahashi N, Okazaki S, Ishibashi K, Hayashi S, Ohsaki Y, Miyokawa N, Non-islet cell tumor hypoglycemia caused by intrathoracic solitary fibrous tumor: a case report , J. Cardiothoracic Surgery , vol.9 (11) (p.49 - ) , 2016 , (IF:2.179)
English: 2. Kitada M, Yasuda S, Nana T, Ishibashi K, Hayashi S, Okazaki S, Surgical treatment for mediastinal parathyroid adenoma causing primary hyperparathyroidism. , J. Cardiothoracic Surgery , vol.7 (11) (p.44 - ) , 2016 , (IF:2.179)
English: Masahiro Kitada, Kensuke Yasuda, Kei Ishibashi, Satoshi Hayashi, Yoshinari Matuda, Yoshinobu Ohsaki and Naoyuki Miyokawa, Leiomyoma of the Trachea: a case report , Journal of Cardiothoracic Surgery 2 , vol.10 (78) , 2015 , (IF:1.632)
English: Kitada M, Matsuda Y, Hayashi S, Ishibashi K, Photodynamic diagnosis of pleural malignant lesions with a combination of 5-aminolevulinic acid and intrinsic fluorescence observation systems. , BMC Cancer. , vol.25 (15) (p.174 - ) , 2015 , (IF:3.265)
English: 3. Hayashi S1, Kitada M1, Matsuda Y1, Ishibashi K1, Takahashi N1, Leiomyosarcoma arising in irradiated region after breast-conserving surgery: a case report. , Surg Case Rep , vol.1 (76) , 2015 , (IF:0)
English: Oba MS, Imoto S, Toh U, Wada N, Kawada M, Kitada M, Masuda N, Taguchi T, Minami S, Jinno H, Sakamoto J, Morita S;, Observational study of axilla treatment for breast cancer patients with 1-3 positive micrometastases or macrometastases in sentinel lymph nodes. , Jpn J Clin Oncol , vol.44 (9) (p.876 - 879) , 2014 , (IF:1.7)
English: Kitada M, Matsuda Y, Ishibashi K, Oikawa K, Miyokawa , Spindle cell carcinoma of the breast as complex cystic lesion: a case report , Cancer Biol Med. 2014 Jun;11(2):130-3. , vol.11 (2) (p.130 - 133) , 2014 , (IF:0)
Copyright (C) 2012～ Asahikawa Medical University, All Rights Reserved.